MEGAVAC INJ DIN 00316393
Health Canada record
| Active ingredient(s) | STAPHYLOCOCCUS AUREUS 300 M; STAPHYLOCOCCUS ALBUS 300 M; STREPTOCOCCUS VIRIDANS 33 M; STREPTOCOCCUS PYOGENES 33 M; STREPTOCOCCUS NON-HEMOLYTIC 33 M; PNEUMOCOCCUS (VARIOUS TYPES MIXTURE) 75 M; NEISSERIA CATARRHALIS 75 M; KLEBSIELLA PNEUMONIAE 75 M; HEMOPHILUS INFLUENZAE 75 M |
|---|---|
| Dosage form | Liquid |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07AX OTHER BACTERIAL VACCINES |
| Original market date | 31-Dec-1974 |
| Current status date | 29-Jun-1999 |
| Source | Health Canada DPD |
Establishment licence of the holder
Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing STAPHYLOCOCCUS AUREUS
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02216981 | MRV | HOLLISTER-STIER LABORATORIES LLC | Suspension | STAPHYLOCOCCUS AUREUS 1200 M; STREPTOCOCCUS (VIRIDANS AND NON-HEMOLYTIC) 200 M; STREPTOCOCCUS (DIPLOCOCCUS) PNEUMONIAE 150 M; NEISSERIA CATARRHALIS 150 M; KLEBSIELLA PNEUMONIAE 150 M; HEMOPHILUS INFLUENZAE 150 M | Cancelled Post Market |